TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Author:

Dreger Peter1,Schnaiter Andrea2,Zenz Thorsten123,Böttcher Sebastian4,Rossi Marianna5,Paschka Peter2,Bühler Andreas2,Dietrich Sascha1,Busch Raymonde6,Ritgen Matthias4,Bunjes Donald2,Zeis Matthias7,Stadler Michael8,Uharek Lutz9,Scheid Christof10,Hegenbart Ute1,Hallek Michael10,Kneba Michael4,Schmitz Norbert7,Döhner Hartmut2,Stilgenbauer Stephan2

Affiliation:

1. Department of Medicine V, University of Heidelberg, Heidelberg, Germany;

2. Department of Medicine III, University of Ulm, Ulm, Germany;

3. Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany;

4. Department of Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany;

5. Division of Hematology, University of Pavia, Pavia, Italy;

6. Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany;

7. Department of Hematology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany;

8. Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany;

9. Department of Medicine for Hematology, Oncology and Tumor Immunology, Charite Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin, Germany; and

10. Department of Medicine I, Center for Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany

Abstract

Key Points This trial update shows that allotransplantation can provide long-term minimal residual disease–negative disease control in poor-risk chronic lymphocytic leukemia. Six-year survival is close to 60% and is independent of the presence of TP53, SF3B1, and NOTCH1 mutations in the tumor clone.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 94 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024;Journal of the National Comprehensive Cancer Network;2024-04

2. Hematopoietic Cell Transplantation and Other Cellular Therapies for Chronic Lymphocytic Leukemia;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

3. Introduction on Stem Cell Therapy and Regeneration;Comprehensive Hematology and Stem Cell Research;2024

4. MRD-directed therapy in CLL: ready for prime time?;Hematology;2023-12-08

5. Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?;Acta Haematologica;2023-10-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3